<DOC>
	<DOC>NCT00044018</DOC>
	<brief_summary>The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.</brief_summary>
	<brief_title>CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Subject must be diagnosed with multiple myeloma (with measurable MProtein in serum and/or urine), and be considered to have disease progression after at least two cycles of treatment or have relapsed after treatment. Subject must understand and voluntarily sign an informed consent document. Subject must not have received corticosteroids, other chemotherapy, thalidomide, or other investigational agents, within 21 days of baseline ECOG (Zubrod) performance status of 0 to 2. Subject must be able to adhere to the study visit schedule and other protocol requirements. Women of childbearing potential (WCBP ) must have a negative serum or urine pregnancy test within 7 days of baseline. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intrauterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Revimid</keyword>
	<keyword>CC5013</keyword>
</DOC>